Novartis' CLEAR study shows Cosentyx superior to Stelara in delivering long …

Novartis' CLEAR study shows Cosentyx superior to Stelara in delivering long …

In addition, Cosentyx is the first IL-17A inhibitor with positive phase III results for the treatment of active psoriatic arthritis and active ankylosing spondylitis and is now approved in Europe, the US, Ecuador, Bangladesh and the Philippines for

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.